**Supplementary Table 1**. Univariable and multivariable Cox’ regression analysis for disease specific survival following radical cystectomy and pelvic lymph-node dissection among 242 pN-positive patients with at least 14 LNs retrieved in their specimen.

|  |  |  |
| --- | --- | --- |
|  | **Univariable** | **Multivariable** |
|  |  | **Model 1** | **Model 2** | **Model 2** |
| **Variable** | **HR 95% CI** | **p** | **HR 95% CI** | **p** | **HR 95% CI** | **p** | **HR 95% CI** | **p** |
| **Age (years)**, as cont. | 1.02 (1.01 - 1.04) | 0.007 | 1.01 (0.99 - 1.02) | 0.5 | 1.01 (0.99 - 1.02) | 0.4 | 1.01 (0.99 - 1.02) | 0.3 |
| **Sex**MaleFemale | 1.00 (Ref.)1.00 (0.70 - 1.44) | -0.9 | - | - | - | - | - | - |
| **pT stage**NMIBC -pT2pT3-4 | 1.00 (Ref.)1.56 (0.99 - 2.4) | -0.054 | 1.00 (Ref.)1.18 (0.74 - 1.90) | -0.5 | 1.00 (Ref.)1.17 (0.73 - 1.88) | -0.4 | 1.00 (Ref.)1.19 (0.74 - 1.90) | -0.5 |
| **pN stage**pN1pN2-3 | 1.00 (Ref.)1.78 (1.25 - 2.55) | -0.001 | 1.00 (Ref.)1.33 (0.87 - 2.04) | -0.2 | 1.00 (Ref.)1.28 (0.83 - 1.96) | -0.23 | 1.00 (Ref.)1.40 (0.93 - 2.11) | -0.11 |
| **LVI**AbsencePresence | 1.00 (Ref.)1.57 (1.05 - 2.35) | -0.028 | 1.00 (Ref.)1.16 (0.75 - 1.79) | -0.5 | 1.00 (Ref.)1.17 (0.76 - 1.81) | -0.5 | 1.00 (Ref.)1.16 (0.75 - 1.78) | -0.5 |
| **Concomitant CIS**AbsencePresence | 1.00 (Ref.)0.82 (0.59 - 1.12) | -0.2 | 1.00 (Ref.)0.93 (0.67 - 1.28) | -0.7 | 1.00 (Ref.)0.93 (0.67 - 1.28) | -0.6 | 1.00 (Ref.)0.90 (0.65 - 1.25) | -0.5 |
| **PSMs**AbsencePresence | 1.00 (Ref.)1.17 (0.65 - 2.10) | -0.6 | - | - | - | - | - | - |
| **VH**AbsencePresence | 1.00 (Ref.)0.94 (0.66 - 1.32) | -0.7 | - | - | - | - | - | - |
| **N. of LNs removed**, as cont. | 0.99 (0.97 - 1.02) | 0.6 | - | - | - | - | - | - |
| **N. of positive LNs**, as cont. | 1.01 (1.01 - 1.02) | 0.007 | - | - | - | - | 1.03 (1.00 - 1.06) | 0.036 |
| **LN density (%)**, as cont. | 1.02 (1.00 - 1.01) | < 0.001 | - | - | 1.01 (1.00 - 1.02) | 0.012 | - | - |
| **LN density**< 20%≥ 20% | 1.00 (Ref.)1.78 (1.30 - 2.44) | -< 0.001 | 1.00 (Ref.)1.48 (1.03 - 2.14) | -0.035 | - | - | - | - |
| **Adjuvant radiotherapy**AbsencePresence | 1.00 (Ref.)0.85 (0.43 - 1.67) | -0.6 | - | - | - | - | - | - |
| **Adjuvant chemotherapy**AbsencePresence | 1.00 (Ref.)0.46 (0.34 - 0.62) | -< 0.001 | 1.00 (Ref.)0.51 (0.36 - 0.72) | -< 0001 | 1.00 (Ref.)0.48 (0.34 - 0.69) | -< 0.001 | 1.00 (Ref.)0.49 (0.37 - 0.70) | -< 0.001 |
| **Center**Center 1Center 2Center 3Center 4Center 5Center 6Center 7Center 8Center 9 | 1.00 (Ref.)2.00 (0.69 - 5.98)3.32 (0.89 - 4.39)1.12 (0.32 - 4.17)1.27 (0.50 - 3.24)2.06 (0.76 - 5.68)0.75 (0.20 - 2.75)0.87 (0.23 - 3.36)3.12 (0.51 - 4.12) | -0.20.10.90.60.20.70.80.3 | - | - | - | - | - | - |

Abbreviations are as follows: HR: hazard ratio; CI: confidence interval; pT stage: pathological tumor stage; pN stage: pathological nodal stage; LVI: lymphovascular invasion; CIS: carcinoma in situ; PSMs: positive surgical margins; VHs: variant histologies; LN: lymph node.